KRAS and lung carcinoma: Previous studies have demonstrated that KRAS-SHP2-MAP kinase pathway-targeted agents induce expression of multiple chemokines in KRAS-mutant lung cancer cell lines (21, 44, 45) and may provide a mechanism by which oncogene-targeted drugs induce cross-talk between cancer cells and the tumor microenvironment.